Refractory and new-onset diabetes more than 5 years after gastric bypass for morbid obesity
Surgical Endoscopy, 05/03/2012
Yamaguchi CM et al. – This is the first investigation, to the best of the knowledge, to underscore the correlates of refractory and new–onset diabetes (NOD) within the bariatric context. Further studies are recommended as such information could be valuable for patient selection, prognostic scoring, and outcome monitoring.
Patients submitted to Roux-en-Y gastric bypass were classified as group I, elevated FBG, and group II, normal controls.
Those in group I with improvement in FBG were defined as responsive and the others as refractory.
Group II participants progressing to new-onset diabetes (NOD) or prediabetes represented NOD cases; the remaining were listed as stable controls.
FBG was the main endpoint, but HbA1c results were considered, along with diet composition and general biochemical profile.
Among 97 selected patients, 51 belonged to group I (52.4 ± 10.5 years, 29.6 % males, initial body mass index (BMI) 58.4 ± 13.4, current BMI 35.1 ± 8.4 kg/m2) and 46 to group II (48.2 ± 10.5 years, 19.6 % males, initial BMI 55.5 ± 8.8, current BMI 33.9 ± 6.9 kg/m2).
Follow-up was 7–9 years, and 31.4 % (16/51) of group I were classified as refractory, whereas 15.2 % (7/46) of the controls converted to NOD.
Multivariate analysis pointed out higher current BMI, older age, consumption of antidiabetic drugs, and male gender as features of refractory cases, whereas NOD participants were not significantly different from non-progressing controls.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.